Ireland Breast Cancer Therapeutics Market Report 2022 to 2030

Ireland Breast Cancer Therapeutics Market Analysis

$ 3999

The Ireland breast cancer therapeutics market is expected to witness significant growth from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of xx% for the year 2022-2030 due to the increasing prevalence of breast cancer and postmenopausal obesity in Ireland. The market is segmented by therapy, by cancer type, and by distribution channel. Perrigo, Alexion Pharmaceuticals, and AstraZeneca are leading companies in Ireland's breast cancer therapeutics market.

ID: IN10IEPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Ireland AUTHOR: Parul Choudhary

Buy Now

Ireland Breast Cancer Therapeutics Market Executive Analysis

The Ireland breast cancer therapeutics market size is at around $xx Bn in 2022 and is projected to reach $xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period. More than $1.20 Bn was allocated in the budget for 2022 for the improvement and expansion of the healthcare system. For 2022, the same additional financing that was made available in 2021 was made accessible. In fact, a further $1.09 Bn has been set aside for 2022, including over $327.23 Mn for new initiatives, bringing the total core funds set aside for current expenses to almost $22.25 Bn. The budget also emphasizes the importance of funding for women's health, which will increase by $33.81 Mn in 2022. Budget 2022 will allocate an additional $51.27 Mn for mental health out of a total budget of $1.25 Bn.

In Ireland, more than 3,500 women and about 35 men receive a breast cancer diagnosis each year. Women over 50 are more likely to have it. All women between the ages of 50 and 70 are eligible for free breast screenings every three years through the Northern Ireland Breast Screening Programme. In advanced breast cancer patients with low levels of the HER2 protein, the new medication known as the "magic bullet" (trastuzumab deruxtecan), which targets cancer directly without affecting the body's healthy cells, has been made available in Cork, Limerick, and Dublin hospitals as part of international clinical trials in Ireland. Participants in the trial saw tumor growth cessation for an average of 10 months, which is twice as long as other patients who got conventional treatment. Trastuzumab deruxtecan is drawn to the presence of HER2 in cancer cells. It minimizes some of the common adverse effects of chemotherapy by delivering potent chemotherapy that is coupled to the antibody directly to the cancer cell.

Market Dynamics

Market Growth Drivers

Ireland's breast cancer therapeutics market will grow as a result of the country's increasing breast cancer incidence. In addition to this, the market will grow as more people adopt a western lifestyle, become more conscious of breast cancer, discontinue nursing earlier, and experience an increase in postmenopausal obesity among women.

Market Restraints

The Ireland breast cancer therapeutics market is hampered by concerns about the adverse effects of medications, high treatment costs, and Ireland's restrictive healthcare coverage laws for breast cancer.

Competitive Landscape

Key Players

MSD (IRL)
Gilead Sciences (IRL)
Perrigo (IRL)
Alexion Pharmaceuticals (IRL)
AstraZeneca
Eli Lilly
F. Hoffmann-La Roche
Novartis

Healthcare Policies and Regulatory Landscape

The public health system, known as the Health Service Executive (HSE), in Ireland provides coverage for breast cancer. This indicates that persons with a current medical card or who qualify for a GP visit card are covered for the cost of breast cancer treatment, including surgery, radiation therapy, and chemotherapy. Even without a working medical card or GP visit card, some people can still get care using private health insurance or by paying out-of-pocket. The National Cancer Control Program (NCCP) also offers recommendations for breast cancer detection and care in Ireland.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Ireland Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.